- Home
- SF vs ABVX Comparison
SF vs ABVX Comparison
Compare SF & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SF | ABVX |
|---|---|---|
| Founded | 1890 | 2013 |
| Country | United States | France |
| Employees | 9000 | 69 |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 11.9B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SF | ABVX |
|---|---|---|
| Price | $77.27 | $135.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $90.33 | ★ $131.31 |
| AVG Volume (30 Days) | 1.3M | ★ 2.2M |
| Earning Date | 04-22-2026 | 03-23-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.58 | $52.14 |
| Revenue Next Year | $8.03 | $4,132.27 |
| P/E Ratio | $20.53 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $67.81 | $9.96 |
| 52 Week High | $134.74 | $148.83 |
Technical Indicators
Market Signals| Indicator | SF | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 59.40 | 58.74 |
| Support Level | $75.78 | $106.03 |
| Resistance Level | $79.12 | $148.41 |
| Average True Range (ATR) | 1.82 | 5.26 |
| MACD | 0.51 | 0.26 |
| Stochastic Oscillator | 81.40 | 35.22 |
Price Performance
Historical ComparisonAbout SF Stifel Financial Corporation
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from trading and investment banking.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.